 ACE inhibition enhances fibrinolysis and decreases inflammation following cardiopulmonary bypass. The short-term effect of both ACE inhibition and angiotensin II type 1 AT1 receptors on markers of fibrinolysis and inflammation during dialysis are currently being studied. 